Data Management And Sharing System of China National Clinical Research Center for Neurological Diseases
Molecular and clinical characterization of TIM-3 in glioma through 1,024 samples
First author：Li, Guanzhang Wang, Zheng
Corresponding author：Zhang, Wei Jiang, Tao
essential_information
- Person in charge：Li, Guanzhang Wang, Zheng
- Data Sources： OTHERS
- Number of papers：OTHERS20190477
- Published time：2017-07-28
2017-07-28
Published articles
Journal：Oncoimmunology
Publication type: Original Research
IF(IF): 8.11
PMID: 28919992 Link To Pubmed Full text Download
Background And Purpose
Method
A cohort of 325 glioma patients with RNA-seq data from Chinese Glioma Genome Atlas (CGGA project) was analyzed, and the results were well validated in TCGA RNA-seq data of 699 gliomas. R language was used as the main tool for statistical analysis and graphical work
Conclusion
The expression of TIM-3 is closely related to the pathology and molecular pathology of glioma. Meanwhile, in glioma TIM-3 plays a specific role in T cell tumor immune response. Therefore, TIM-3 is a promising target for immunotherapeutic strategies, providing an alternative treatment when glioma gains resistance to antibodies of PD-1/PD-L1.
Main results
TIM-3 was enriched in glioblastoma (the most malignant glioma) and IDH-wildtype glioma. TIM-3 can act as a potential marker for mesenchymal molecular subtype according to TCGA transcriptional classification scheme in glioma. TIM-3 was closely related to immune functions in glioma, especially T cell mediated immune response to tumor cell and T cell mediated cytotoxicity directed against tumor cell target. Moreover, TIM-3 and PD-L1 played almost exactly the same inflammatory activation functions in glioma. Clinically, high expression of TIM-3 was an independent indicator of poor prognosis.